AstraZeneca's ovarian cancer drug gets NICE approval
Anglo-Swedish drug major AstraZeneca (LSE: ANZ) on Wednesday said the National Institute for Health and Care Excellence (NICE) has recommended its Lynparza (olaparib) to treat ovarian cancer.
Clinical commissioning groups, NHS England and local authorities are required to comply with this recommendation and ensure that olaparib treatment is funded and accessible within 90 days, the company said in a statement.
Greg Rossi, oncology business unit head at AstraZeneca UK, said: “AstraZeneca is delighted that NHS patients in England will soon have access to the first targeted therapy for ovarian cancer. Olaparib is a product of the British science community and it is only right that patients in this country should have the opportunity to benefit from treatment. We hope that NHS England will issue its commissioning policy as soon as possible to allow funding and rapid patient access to olaparib.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze